- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06255782
Открытое исследование по изучению ECUR-506 у младенцев мужского пола в возрасте до 9 месяцев с неонатальным дебютом безрецептурного дефицита (OTC-HOPE)
Первое открытое исследование фазы I/II с увеличением дозы на людях для оценки безопасности и эффективности однократного внутривенного (в/в) введения ECUR-506 у мужчин в возрасте до 9 месяцев с генетически подтвержденным неонатальным началом Дефицит орнитин-транскарбамилазы (ОТС)
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls.
This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is an approach used to repair, replace, or introduce functional copies of genes that are not working properly. ECUR-506 contains a functional copy of the OTC gene, along with a gene to encode an editing enzyme that enables insertion of the OTC gene into the genome. The study drug is administered as a single IV infusion. Because genes cannot enter cells on their own, ECUR-506 uses a delivery system based on adeno-associated virus (AAV), a commonly used viral vector, to transport the genetic material into cells.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
New South Wales
-
Sydney, New South Wales, Австралия
- The Children's Hospital at Westmead
-
-
Victoria
-
Melbourne, Victoria, Австралия, 3052
- The Royal Children's Hospital
-
-
-
-
-
Barcelona, Испания, 08950
- Hopsital Sant Joan de Deu
-
Madrid, Испания, 28041
- Hospital Universitario 12 de Octubre
-
-
-
-
-
London, Соединенное Королевство
- Great Ormond Street Hospital
-
Newcastle upon Tyne, Соединенное Королевство
- The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital
-
-
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90095
- UCLA Mattel Children's Hospital
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Children's Hospital of Colorado, Anshutz Medical Campus
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
New York
-
New York, New York, Соединенные Штаты, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health and Science University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Key Inclusion Criteria:
- Male sex
- Gestational or adjusted (corrected) gestational age ≥ 37 weeks
- Age at screening is 24 hours to 7 months
- Weight ≥ 3.5 kg and ≤ 13.5 kg at screening
- Has received age-appropriate vaccinations
- Genetically confirmed OTCD defined by genetic confirmation of an OTC variant (pathogenic or likely pathogenic) associated with severe neonatal OTCD defined below in Inclusion Criteria #7 or has the same OTC variant as a family member who had severe neonatal OTCD within first week of life.
- Severe neonatal OTCD defined by hyperammonemic crisis with elevated ammonia level of >560 μmol/L and clinical symptoms within first week of life, and currently receiving treatment with both dietary protein restriction and nitrogen scavenger therapy.
- Current or historical biochemical profile consistent with OTCD
- Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.
Key Exclusion Criteria:
- Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury
- Requiring urgent liver transplant due to liver failure as assessed by the PI.
- Contiguous gene deletion involving the OTC gene and including at least the CYBB gene on the telomeric side or the TSPAN7 gene on the centromeric side.
- Known or suspected major organ injury/dysfunction/anomalies.
- Vital sign and laboratory abnormalities outside of reference ranges.
- Treatment with any other gene therapy or gene editing therapy
- Co-enrollment in any other study unless approved by the sponsor.
- Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
- Documented vertical transmission of HepA/HepB/HepC
- Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Low Dose Level
Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion. |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
|
Экспериментальный: Intermediate Dose Level
Participants will receive an intermediate dose of ECUR-506 delivered on time via IV infusion |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
|
Экспериментальный: High Dose Level
Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion. |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Treatment-emergent adverse events (incidence, severity, seriousness, and relatedness)
Временное ограничение: Over 24 weeks post infusion
|
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, Pediatric Neurologist exam parameters, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period. AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related. |
Over 24 weeks post infusion
|
|
Physical exam parameters
Временное ограничение: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI assessment of General Appearance, Dermatological, HEENT, Lymphatic, Respiratory, Cardiovascular, Gastrointestinal, Musculoskeletal, Neurological (Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes)) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Vital sign parameters
Временное ограничение: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI assessment of Systolic Blood Pressure, Diastolic Blood Pressure, Pulse Rate, Respiratory Rate, Temperature) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Pediatric neurologist exam parameters
Временное ограничение: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes Pediatric Neurologist assessment of Neurological status by review of Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes.) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Blood safety tests including hematology, serum chemistry, liver function tests, coagulation tests
Временное ограничение: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Blood Safety tests to be reviewed in relation to established normal ranges for each assessment for the applicable age group) |
as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Urinalysis evaluations
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period. AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
12 lead ECG parameters
Временное ограничение: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI review of Heart Rate, PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval, Overall Interpretation) |
as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Complete clinical response
Временное ограничение: Over 24 weeks post infusion
|
Discontinuation of scavenger medication for a minimum duration of 28 days without reductions in prescribed daily protein intake during this time period by end of study. |
Over 24 weeks post infusion
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of HAEs/person-year
Временное ограничение: Day 1 post dose through Week 24
|
Key Secondary Endpoint: Pharmacodynamics and Efficacy |
Day 1 post dose through Week 24
|
|
qPCR measurement to evaluate the clearance of both vectors in body fluids over time
Временное ограничение: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacokinetics |
Over 24 weeks post infusion
|
|
Incidence of hyperammonemic episode (HAE)
Временное ограничение: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Incidence and number of hyperammonemic episodes (HAE/HAC) resulting in hospitalization
Временное ограничение: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Overall and by hospitalization severity (Mild: adjustment of dietary protein intake and oral scavenger medication / Moderate: cessation of dietary protein intake and initiation of IV scavenger therapy / Severe: requirement for hemodialysis)
Временное ограничение: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy. |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
|
|
Duration of hospitalization for each HAE/HAC
Временное ограничение: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Requirement for Intensive Care Unit (ICU) care during hospitalization for each HAE/HAC
Временное ограничение: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Time to liver transplant from dosing to end of study (EOS)
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Supportive Secondary Endpoint: Efficacy |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Transplant free survival
Временное ограничение: Time to lever transplant or any-cause death from dosing to EOS
|
Supportive Secondary Endpoint: Efficacy |
Time to lever transplant or any-cause death from dosing to EOS
|
|
Overall survival
Временное ограничение: Time to any-cause death from dosing to EOS
|
Supportive Secondary Endpoint: Efficacy |
Time to any-cause death from dosing to EOS
|
|
Achieving and maintaining complete clinical response through end of study
Временное ограничение: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Over 24 weeks post infusion
|
|
Scavenger drug dose
Временное ограничение: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Over 24 weeks post infusion
|
|
Dietary protein intake g/kg/day
Временное ограничение: Supportive Secondary: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Supportive Secondary: Over 24 weeks post infusion
|
|
Blood urea nitrogen measurements
Временное ограничение: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics |
Over 24 weeks post infusion
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Clinical Response (CR) defined as reduction in baseline standard of care therapy
Временное ограничение: Assessed at Week 24
|
Efficacy |
Assessed at Week 24
|
|
Serum Neurofilament Light Chain
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Safety |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to AAVrh79 capsid in blood
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to hOTC transgene in blood
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to M2PCSK9 transgene in blood
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Incidence and time to medical management adjustments based on iECURE guidance (protein diet or scavenger medication)
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Efficacy |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Fasting plasma ammonia
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Fasting plasma citrulline and fasting plasma glutamine levels
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Serum PCSK9
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary excretion of phenylacetate metabolites
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary phenylacetate (mcg/mL), urinary phenylacetylglutamine (mcg/mL), urinary phenylacetate/ phenylglutamine ratio. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary excretion of orotic acid metabolites.
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary orotic acid (mmol/ mol creatinine), urinary uracil (mmol/mol creatinine). |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary nitrogen to urinary creatinine ratio.
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary nitrogen to urinary creatinine ratio (mg/dL) |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Change from baseline at Week 24 post infusion in length.
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Length measured in centimeters. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Change from baseline at Week 24 post infusion in weight.
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Weight measured in kilograms. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Percent liver transduction via ISH/IF (in-situ hybridization / Immunofluorescence)"at Wk 24 collected by liver biopsy.
Временное ограничение: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess the potential on and "off" target editing by amplicon-seq in liver tissue samples of participants who received ECUR-506.
Временное ограничение: The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess potential off-target editing with AAV vector ITR insertion by ITR-seq in liver tissue samples of participants who received ECUR-506
Временное ограничение: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess for potential genetic changes in the liver tissue, collected by liver biopsy, through long read sequencing, in participants who have received ECUR-506
Временное ограничение: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
With an observed genetic safety signal, genetic analysis of Whole Blood DNA may be performed on samples collected and stored at screening and week 24, in the event of an observed genomic safety signal.
Временное ограничение: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Safety |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
|
Change from baseline at Week 24 post infusion in Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales
Временное ограничение: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Total Raw Scores, Growth Score Values (GSVs), and Age Equivalent Scores will be analyzed; Raw Scores range 0-162; GSVs range 428-599; Age Equivalent Scores range 1-42 months; a higher score reflects a higher level of skill. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Quality of Life, as measured by the Pediatric QOL inventory Infant Scale (PedsQL-IS)
Временное ограничение: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Quality of Life |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: George Diaz, M.D., Ph.D, iECURE, Inc.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
- Заболевания нервной системы
- UCD
- Заболевания центральной нервной системы
- Болезнь печени
- Генетические заболевания, врожденные
- Х-связанный
- Аммиак
- Неонатальный
- Заболевания головного мозга
- Метаболические заболевания
- Метаболизм
- Метаболизм, врожденные ошибки
- Нарушения цикла мочевины
- Пересадка печени
- Наследственные метаболические нарушения
- Заболевания головного мозга, Метаболические, Врожденные
- Генетические заболевания, сцепленные с Х-хромосомой
- Врожденный
- Врожденные ошибки
- Безрецептурный
- Заболевания головного мозга, Метаболические
- Безрецептурный дефицит
- ОТКР
- Орнитин
- Транскарбамилаза
- Дефицит орнитинтранскарбамилазы
- Гипераммониемия
- Метаболизм аминокислот, врожденные ошибки
- Высокий уровень аммиака
- NH4
- Нейрометаболические расстройства
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Заболевания пищеварительной системы
- Врожденные, наследственные и неонатальные заболевания и аномалии
- Патологические состояния, признаки и симптомы
- Пищевые и метаболические заболевания
- Генетические заболевания, врожденные
- Заболевания печени
- Заболевания головного мозга
- Заболевания нервной системы
- Заболевания центральной нервной системы
- Метаболические заболевания
- Метаболизм, врожденные ошибки
- Заболевания головного мозга, Метаболические
- Генетические заболевания, сцепленные с Х-хромосомой
- Дефицит орнитинкарбамоилтрансферазы
- Нарушения цикла мочевины, врожденные
- Метаболизм аминокислот, врожденные ошибки
- Гипераммониемия
- Заболевания головного мозга, Метаболические, Врожденные
Другие идентификационные номера исследования
- ECUR-506-OTC-101
- OTC-HOPE (Другой идентификатор: iECURE, Inc.)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .